NCT02865538View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

March 28, 2017

Study Completion Date

March 28, 2017

Conditions
Post-menopausal Vasomotor Symptoms
Interventions
DRUG

BAY3427080

DRUG

Placebo (for BAY3427080)

Trial Locations (3)

32720

Avail Clinical Research, DeLand

33143

QPS/MRA (Miami Clinical Research), Miami

78209

ICON Clinical Research Unit, San Antonio

Sponsors

Lead Sponsor

Bayer

Collaborators (1)

Nerre Therapeutics Ltd.
All Listed Sponsors
collaborator

Nerre Therapeutics Ltd.

INDUSTRY

lead

Bayer

INDUSTRY